Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T47D | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7543.084 | 1.0013 | 1.0019 | 1.3431 | |
| T47D | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7543.084 | 1.0205 | 1.0305 | 1.3431 | |
| T47D | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7543.084 | 0.9676 | 0.9516 | 1.3431 | |
| T47D | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7543.084 | 0.5148 | 0.2199 | 1.3431 | |
| T47D | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7543.084 | 0.5570 | 0.2936 | 1.3431 | |
| T47D | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7543.084 | 0.6682 | 0.4814 | 1.3431 | |
| T47DKBLUC | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7546.084 | 0.9702 | 0.9365 | 0.9375 | |
| T47DKBLUC | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7546.084 | 0.9722 | 0.9408 | 0.9375 | |
| T47DKBLUC | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7546.084 | 0.9494 | 0.8922 | 0.9375 | |
| T47DKBLUC | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7546.084 | 0.9514 | 0.8965 | 0.9375 | |
| T47DKBLUC | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7546.084 | 0.9552 | 0.9045 | 0.9375 | |
| T47DKBLUC | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7546.084 | 0.9803 | 0.9580 | 0.9375 | |
| T47DKBLUC | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7546.084 | 0.7939 | 0.5635 | 0.9375 | |
| T47DKBLUC | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7546.084 | 0.6243 | 0.2100 | 0.9375 | |
| T47DKBLUC | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7546.084 | 0.9297 | 0.8504 | 0.9375 | |
| ZR-75-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7552.084 | 0.9813 | 0.9668 | 1.1307 | |
| ZR-75-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7552.084 | 1.0068 | 1.0121 | 1.1307 | |
| ZR-75-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7552.084 | 0.9430 | 0.8989 | 1.1307 | |
| ZR-75-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7552.084 | 1.0110 | 1.0195 | 1.1307 | |
| ZR-75-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7552.084 | 1.0229 | 1.0405 | 1.1307 | |
| ZR-75-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7552.084 | 0.9277 | 0.8715 | 1.1307 | |
| ZR-75-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7552.084 | 0.4682 | 0.0221 | 1.1307 | |
| ZR-75-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7552.084 | 0.3572 | -0.1954 | 1.1307 | |
| ZR-75-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7552.084 | 0.0610 | -0.8315 | 1.1307 | |
| ZR-75-1 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.000853 | uM | 7553.085 | 1.0086 | 1.0153 | 1.1198 |